Ruchi Saxena
Overview
Explore the profile of Ruchi Saxena including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
318
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Saxena R, Gottlin E, Campa M, He Y, Patz Jr E
Semin Immunol
. 2025 Jan;
77:101931.
PMID: 39826189
Cancer remains a formidable global health challenge requiring the continued exploration of innovative therapeutic approaches. While traditional treatment strategies including surgery, chemotherapy, and radiation therapy have had some success, primarily...
3.
Clarke J, Simon G, Mamdani H, Gu L, Herndon 2nd J, Stinchcombe T, et al.
Nat Commun
. 2025 Jan;
16(1):93.
PMID: 39747856
GT103 is a first-in-class, fully human, IgG3 monoclonal antibody targeting complement factor H that kills tumor cells and promotes anti-cancer immunity in preclinical models. We conducted a first-in-human phase 1b...
4.
Saxena R, Welsh C, He Y
Front Cell Dev Biol
. 2024 Dec;
12:1462339.
PMID: 39620145
Cancer is a complex disease characterized by specific "mission-critical" events that drive the uncontrolled growth and spread of tumor cells and their offspring. These events are essential for the advancement...
5.
Saxena R, Bushey R, Campa M, Gottlin E, Guo J, Patz Jr E, et al.
J Immunol
. 2024 Apr;
212(10):1589-1601.
PMID: 38558134
Tumor-targeting Abs can be used to initiate an antitumor immune program, which appears essential to achieve a long-term durable clinical response to cancer. We previously identified an anti-complement factor H...
6.
Saxena R, Gottlin E, Campa M, Bushey R, Guo J, Patz Jr E, et al.
Front Cell Dev Biol
. 2024 Feb;
12:1302490.
PMID: 38389705
The elimination of cancer cells critically depends on the immune system. However, cancers have evolved a variety of defense mechanisms to evade immune monitoring, leading to tumor progression. Complement factor...
7.
Vats H, Walia G, Saxena R, Sachdeva M, Gupta V
Neonatology
. 2024 Jan;
121(2):244-257.
PMID: 38198767
Background: Stunting is an important predictor of growth and development of children under 5 years of age, and it remains the significant problem in LMIC. However, LBW emerges as risk...
8.
Bushey R, Saxena R, Campa M, Gottlin E, He Y, Patz E
Mol Cancer Ther
. 2023 Mar;
22(6):778-789.
PMID: 36995981
Development of novel therapeutic antibodies that not only kill tumor cells but modulate the adaptive immune response has the potential to produce long term anticancer immunity and a durable clinical...
9.
Vats H, Saxena R, Sachdeva M, Walia G, Gupta V
Obes Res Clin Pract
. 2021 Nov;
15(6):536-545.
PMID: 34782256
Objective: Systematic review and meta-analysis conducted to investigate the effect of stratified pre-pregnancy maternal body mass index on twenty maternal and fetal/neonatal adverse outcomes. Methods: PubMed, Google Scholar, Medline, Embase,...
10.
McLeod I, Saxena R, Carico Z, He Y
Front Cell Dev Biol
. 2021 Aug;
9:709398.
PMID: 34458267
Autophagy, a highly conserved intracellular process, has been identified as a novel mechanism regulating T lymphocyte homeostasis. Herein, we demonstrate that both starvation- and T cell receptor-mediated autophagy induction requires...